Nibel (Nebivolol)

Nebivolol, the active ingredient in Nibel, is a beta blocker presented as an oral tablet for oral use. It selectively blocks β1‑adrenergic receptors while enhancing nitric‑oxide release, helping to lower blood pressure and improve cardiac function in patients with hypertension and heart failure.

GNH USA supplies Nibel as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals, pharmacies and clinics worldwide, ensuring consistent quality, regulatory compliance, and reliable supply chain management for healthcare providers.

Nebivolol is used to manage conditions within the cardiovascular disease spectrum, primarily by lowering blood pressure and supporting heart function.

Hypertension: reduces systolic and diastolic blood pressure, decreasing cardiovascular risk. Heart failure: improves left‑ventricular ejection fraction and lowers hospitalization rates. Chronic heart failure with reduced ejection fraction: enhances cardiac output and symptom control.

Nebivolol may cause a range of adverse reactions, varying from mild to serious.

Common Side Effects: - Headache - Dizziness - Fatigue - Nausea - Bradycardia - Peripheral edema

Serious or Rare Side Effects: - Severe bradycardia - Marked hypotension - Bronchospasm, especially in asthma/COPD - AV block or heart block - Allergic reactions (rash, angioedema) - Hepatic dysfunction

When prescribing Nebivolol, clinicians should consider several safety measures to minimize risks.

Monitor blood pressure: check regularly during initiation and dose adjustments. Assess cardiac function: especially in patients with heart failure or conduction disorders. Caution in asthma or COPD: beta‑blockade may precipitate bronchospasm. Avoid abrupt discontinuation: may lead to rebound hypertension or tachycardia. Adjust dose in renal impairment: monitor renal function and modify as needed. Store at room temperature: keep in original packaging, protect from moisture and light.

Nebivolol can interact with other medicines, altering its efficacy or safety profile.

Major Interactions (Avoid): - Combined with other β‑blockers: risk of excessive bradycardia. - Concomitant use with non‑dihydropyridine calcium channel blockers (verapamil, diltiazem): may cause severe AV block. - Potent CYP2D6 inhibitors (paroxetine, fluoxetine, quinidine): increase nebivolol plasma concentrations.

Moderate Interactions (Monitor Closely): - Co‑administration with diuretics: may enhance hypotensive effect. - Use with ACE inhibitors or ARBs: additive blood‑pressure lowering. - Concurrent antihypertensives (e.g., hydralazine): may require dose adjustment. - NSAIDs: may reduce antihypertensive efficacy.